GUTS Stock Forecast & Price Target

Fractyl Health is viewed favorably because Revita has shown unusually durable post-GLP-1 weight maintenance after a single minimally invasive procedure, with REVEAL-1 patients retaining about 78% of prior drug-induced weight loss at one year and 100% of participants staying within 10% regain at six months. The thesis is reinforced by a clear dose-response signal from ablation length, supportive cardiometabolic improvements, and the company’s belief that the pivotal REMAIN-1 cohort is powered with more than 300 patients and over 90% power, positioning the 3Q26 midpoint readout and 4Q26 pivotal data as meaningful catalysts. Financially and strategically, the company says cash runway extends into early 2027, while FDA feedback, potential De Novo classification, and the RAPID pathway could reduce regulatory and reimbursement friction, improving commercialization odds.

Fractyl Health is viewed negatively because its valuation depends heavily on a clinical-stage NPV model and a narrow set of assumptions around Revita, with only 60% probability of success assigned and full contribution from a single program. Although post-hoc data and the 300+ patient pivotal cohort are encouraging, the investment case remains exposed to failed or inconclusive trials, uncertain pricing and market penetration, and delays in adding Rejuva or other pipeline assets. The company also faces substantial financing risk, including the need to secure adequate funding, the possibility of dilutive capital raises, and even delisting risk if exchange requirements are not met.